Search hospitals > South Carolina > Myrtle Beach
Carolina Urologic Research Center
Claim this profileMyrtle Beach, South Carolina 29572
Global Leader in Prostate Cancer
Global Leader in Bladder Cancer
Conducts research for Cancer
Conducts research for Transitional Cell Carcinoma
Conducts research for Benign Prostatic Hyperplasia
158 reported clinical trials
3 medical researchers
Summary
Carolina Urologic Research Center is a medical facility located in Myrtle Beach, South Carolina. This center is recognized for care of Prostate Cancer, Bladder Cancer, Cancer, Transitional Cell Carcinoma, Benign Prostatic Hyperplasia and other specialties. Carolina Urologic Research Center is involved with conducting 158 clinical trials across 69 conditions. There are 3 research doctors associated with this hospital, such as Neal Shore, Robert Jansen, MD, and Abhishek Srivastava, MD.Area of expertise
1Prostate Cancer
Global LeaderStage IV
PSA
DDR negative
2Bladder Cancer
Global LeaderStage IV
Stage III
FGFR3 positive
Top PIs
Neal ShoreCarolina Urologic Research Center4 years of reported clinical research
Expert in Prostate Cancer
Studies Bladder Cancer
35 reported clinical trials
53 drugs studied
Robert Jansen, MDCarolina Urologic Research Center3 years of reported clinical research
Studies Prostate Cancer
1 reported clinical trial
2 drugs studied
Abhishek Srivastava, MDCarolina Urologic Research Center1 year of reported clinical research
Studies Bladder Cancer
1 reported clinical trial
1 drug studied
Clinical Trials running at Carolina Urologic Research Center
Bladder Cancer
Prostate Cancer
Transitional Cell Carcinoma
Recurrence
Urologic Cancers
Tumors
Carcinoma
Cancer
Follicular Lymphoma
Small Cell Lung Cancer
Pembrolizumab + BCG
for Bladder Cancer
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.
Recruiting2 awards Phase 39 criteria
TAR-200 vs Chemotherapy
for Bladder Cancer
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Recruiting2 awards Phase 32 criteria
CG0070
for Bladder Cancer
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Carolina Urologic Research Center?
Carolina Urologic Research Center is a medical facility located in Myrtle Beach, South Carolina. This center is recognized for care of Prostate Cancer, Bladder Cancer, Cancer, Transitional Cell Carcinoma, Benign Prostatic Hyperplasia and other specialties. Carolina Urologic Research Center is involved with conducting 158 clinical trials across 69 conditions. There are 3 research doctors associated with this hospital, such as Neal Shore, Robert Jansen, MD, and Abhishek Srivastava, MD.